Navigation Links
Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of $.10 on Revenues of $27.6 Million
Date:7/31/2008

conference call on July 31, 2008 at 9:00 a.m. Eastern Time to discuss second quarter results. You are invited to listen to the conference call by dialing 706-643-1624. The conference will also be simultaneously webcast at http://www.osteotech.com. Automated playback will be available two hours after completion of the live call, through midnight, Thursday, August 14, 2008, by dialing 706-645-9291 and indicating access code 52377240.

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients in the repair of the musculoskeletal system through the development of innovative therapy-driven products that alleviate pain, promote biologic healing and restore function. For further information regarding Osteotech, this press release or the conference call, please go to Osteotech's website at http://www.osteotech.com.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
2. Osteotech Completes Tissue Supply Agreement With LifeNet Health
3. Osteotech Announces Third Quarter Earnings Release and Conference Call Schedule
4. Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09
5. Osteotech Signs Agreement To Distribute Harvest Technologies BMAC(TM) System
6. Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market
7. Osteotech Announces the Unexpected Passing of Audit Committee Member Leads to Receipt of Nasdaq Deficiency Letter
8. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
9. Haemacure Reports Third Quarter 2007 Results
10. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
11. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014. Kessler Foundation researchers have published a study ... the executive deficits found in individuals with multiple ... for executive deficits in multiple sclerosis? Evidence from ... ahead of print on August 18 by ... Victoria Leavitt, PhD, of the Manhattan Memory Center, ...
(Date:9/16/2014)... prospective study that compared patient-reported outcomes of a ... demonstrates that single fraction radiation therapy (SFRT) is ... (MFRT) when pain, function and quality of life ... the American Society for Radiation Oncology,s (ASTRO,s) 56th ... in patients, pain, function and degree of distress ...
(Date:9/16/2014)... presented at the ESMO 2014 Congress will be published ... to give you a first glimpse of what you ... the leading theme Precision Medicine in Cancer Care. , ... is now possible for an increasing number of cancers. ... a common goal --improved patient outcomes. This is the ...
(Date:9/16/2014)... 2014 The Pain Center of ... Ranking Arizona magazine, has selected Analance ™, ... , With TPC seeing hundreds of thousands of ... that was managed through “home grown” systems trying to ... clinical leadership teams. “Our current tools were not ...
(Date:9/16/2014)... September 16, 2014 Transparency Market Research, ... the global facial care market is expected to report ... report, titled ‘Facial Care Market (By Product Type - ... Cleansing Wipes, Serums and Masks and Others (fade creams, ... Growth, Trends and Forecast 2013 – 2019,’ is now ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:ESMO 2014 Congress Preview 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 2Health News:The Pain Center of Arizona (TPC) Implements Analance™ BI for Actionable Intelligence 3Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 2Health News:Global Facial Care Market Will Report a CAGR of 6.9% between 2013 and 2019: Transparency Market Research 3
... Masimo (Nasdaq: MASI ),the inventor of Pulse ... today that the Pricing Committee of its Board of,Directors ... plan is designed to enhance the Board,s ability to ... company,that do not offer an adequate price to all ...
... AKL, MONTREAL, Nov. 9 /PRNewswire-FirstCall/ - Akela ... on developing therapies for the,inhalation and pain markets, ... accounting principles for the three and six,month period ... consolidated net loss for the third quarter of ...
... on what footwear works best , , FRIDAY, Nov. 9 (HealthDay ... flip-flops and flexible walking shoes than with other types ... to barefoot, the better for the knees, the study finds. ... not only affects your feet but can affect other joints ...
... Stryker Corporation,(NYSE: SYK ) announced today that ... revised from the previous announcement dated,November 1, 2007. ... Piper Jaffray Health Care Conference New York, ... presentation will be available,on Stryker,s website at http://www.stryker.com ...
... 9 Give an Hour, a,non-partisan, non-profit organization offering ... ones, announces there are 750,providers nationwide on its network., ... network 10 percent, or 40,000,people, of the approximately 400,000 ... average fee of $100 an hour, this would save,the ...
... only realistic way of preventing deaths and severe complications ... the disease, concludes research published ahead of print in ... healthcare workers and others likely to be at risk ... immunised in the UK. But vaccination programmes for children ...
Cached Medicine News:Health News:Masimo Corporation Adopts Stockholder Rights Plan 2Health News:Masimo Corporation Adopts Stockholder Rights Plan 3Health News:Akela Pharma reports results for third quarter of fiscal 2007 2Health News:Akela Pharma reports results for third quarter of fiscal 2007 3Health News:Akela Pharma reports results for third quarter of fiscal 2007 4Health News:Close to Barefoot Best for Arthritic Knees 2Health News:Close to Barefoot Best for Arthritic Knees 3Health News:Close to Barefoot Best for Arthritic Knees 4Health News:Stryker to Present at Investor Conference 2Health News:Non-Profit Calls on Mental Health Professionals to Honor Veterans Day by 'Giving an Hour' of Free Counseling to Returning Veterans 2Health News:Chicken pox vaccination should be introduced for children in the UK 2
(Date:9/16/2014)... , Sept. 16, 2014 On September 25 ... exhibition focusing on medical design and manufacturing - MEDTEC ... Shanghai World Expo Exhibition & Convention Center, bringing together ... and regions to showcase their latest medical-grade raw materials, ... only one week remaining for free visitor pre-registration to ...
(Date:9/16/2014)... , Sept. 16, 2014 The Lupus ... LLY ) today released results from UNVEIL: ... sheds light on the lupus journey and the challenges ... for lupus caregivers. The UNVEIL study, which involved over ... devastating impact lupus has on all aspects of life ...
(Date:9/16/2014)... Sept. 16, 2014  DNAtrix, Inc., experts in ... patient was treated with the company,s lead product, ... in a randomized, multicenter, open-label Phase Ib study ... in collaboration with leading neurosurgeons and neuro-oncologists in ... of our randomized Phase Ib study of DNX-2401 ...
Breaking Medicine Technology:MEDTEC China 2014: Seven Highlights Not to Miss! 2MEDTEC China 2014: Seven Highlights Not to Miss! 3MEDTEC China 2014: Seven Highlights Not to Miss! 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 2"UNVEIL" Survey Reveals a Life Interrupted by Lupus 3"UNVEIL" Survey Reveals a Life Interrupted by Lupus 4"UNVEIL" Survey Reveals a Life Interrupted by Lupus 5DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... 3 out of 4 Patients in Cohort 2 Demonstrate T-Cell ... Potential ... Biopharmaceuticals,Corporation (TSX: NVN) today announced interim immunological data from the,first ... its lead product,candidate, HspE7, in patients with cervical intraepithelial neoplasia, ...
... 25, Astellas Pharma US, Inc. and its co-development,partner ... COM) announced the first,pivotal Phase III study evaluating ... today in Circulation,the official journal of the American ... the Atrial arrhythmia Conversion Trial (ACT I),the primary ...
Cached Medicine Technology:Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 2Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 3Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 4Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 5Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial 6Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 2Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 3Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 4Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm 5
... Rapidlab 800 System is a fully automated, ... care whole blood parameters in addition to ... allows the basic blood gas model to ... electrolytes, metabolites and CO-oximetry in a single ...
Microcomputer controlled, preparative ultracentrifuge, with CFC-free refrigeration system. Available either internally cooled or with external water cooling. Quikset user interface, Softspin automati...
... Sorvall DiscoveryTMM150 SE Micro-ultra centrifuge continues ... volume sample processing, now with 1,048,000 x ... bucket rotor. DiscoveryTMM150SE processes sample sizes ... a small floor footprint, brushless direct drive, ...
... and environmental safety are the ... K Ultracentrifuge from Beckman Coulter. ... centrifugation technology, the LE-80 K ... provide advanced capability for your ...
Medicine Products: